CASP9 and amyotrophic lateral sclerosis: These findings invite further investigation to explore how caspase-9 activity is systemically dysregulated in ALS and to test if pharmacological approaches targeting caspase-9 can replicate the therapeutic benefit of XIAP overexpression.